Prnewswireยท2025-09-16 12:00Core Insights - Coya Therapeutics, Inc. is developing COYA 303, a proprietary combination of LD-IL-2 and GLP-1RA, aimed at treating diseases like Alzheimer's Disease driven by chronic inflammation [1][2][3] - The initial results from an in vivo study indicate that COYA 303 significantly reduces neuroinflammation and enhances regulatory T cell (Treg) function, suggesting its potential in neurodegenerative conditions [2][3][6] - The company is currently conducting further experimental cohorts to evaluate modified treatment protocols and the timing of treatment initiation [4] Company Overview - Coya Therapeutics is a clinical-stage biotechnology company focused on enhancing Treg function to target systemic and neuroinflammation [5][7] - The company believes that Treg dysfunction is a key factor in various diseases, including neurodegenerative and autoimmune conditions [5][7] - Coya's therapeutic pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy [7] Study Findings - COYA 303 demonstrated significant systemic and central immunomodulatory effects, including enhanced Treg numbers and function, reduced activated myeloid cells, and attenuation of neuroinflammation in the cortex and hippocampus [6] - The findings from the first cohort of the study align with previous in vitro results, reinforcing the potential of COYA 303 in modulating inflammatory pathways associated with Alzheimer's Disease [1][3][6] - The CEO of Coya highlighted the growing interest in GLP-1 receptor agonists as potential therapies beyond metabolic diseases, positioning COYA 303 as a unique approach to address neuroinflammation [5]